文献速递慢性肾脏病遗传性与小管间质肾病

肽转运体2的变异预测卟啉病相关肾病的严重程度

A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease.
PubMed 文献 · J Am Soc Nephrol · 2016-12-28

研究纳入2003至2013年随访的122例急性间歇性卟啉病患者,分析PEPT2基因型与肾病严重程度的关系。携高亲和力变异PEPT2*1*1者肾功能更差,eGFR更低且下降更快,独立关联eGFR<60及年下降>1。

要点

  • PEPT2*1*1携带者末次随访eGFR低于低亲和力变异携带者。
  • PEPT2*1*1基因型独立关联eGFR<60与年下降>1。
  • PEPT2抑制剂防治卟啉病相关肾病需进一步研究。

核心结论

  • PEPT2基因变异可预测急性间歇性卟啉病慢性并发症的严重程度。
  • PEPT2抑制剂预防卟啉病相关肾病的治疗价值有待研究。

研究设计与样本

  • 分析122例急性间歇性卟啉病患者,随访2003至2013年,进行PEPT2基因分型。

主要发现

  • 末次随访平均eGFR:PEPT2*1*1组54.4±19.1 vs PEPT2*1*2组66.6±23.8 vs PEPT2*2*2组78.1±19.9 ml/min per 1.73 m2。
  • 10年eGFR变化:PEPT2*1*1组-11.0±3.3 vs PEPT2*1*2组-2.4±1.9 vs PEPT2*2*2组3.4±2.6 ml/min per 1.73 m2。
  • 末次随访eGFR<60比例:PEPT2*1*1组68% vs PEPT2*1*2组37% vs PEPT2*2*2组15%。
  • PEPT2*1*1独立关联eGFR<60,比值比6.85(95%CI 1.34至46.20)。
  • PEPT2*1*1独立关联年eGFR下降>1 ml/min per 1.73 m2,比值比3.64(95%CI 1.37至9.91)。

关键数值与推荐

  • PEPT2*1*1为高亲和力变异,PEPT2*1*2和PEPT2*2*2为低亲和力变异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CKD occurs in most patients with acute intermittent porphyria (AIP). During AIP, δ-aminolevulinic acid (ALA) accumulates and promotes tubular cell death and tubulointerstitial damage. The human peptide transporter 2 (PEPT2) expressed by proximal tubular cells mediates the reabsorption of ALA, and variants of PEPT2 have different affinities for ALA. We tested the hypothesis that PEPT2 genotypes affect the severity and prognosis of porphyria-associated kidney disease. We analyzed data from 122 individuals with AIP who were followed from 2003 to 2013 and genotyped for PEPT2 At last follow-up, carriers of the PEPT2*1*1 genotype (higher affinity variant) exhibited worse renal function than carriers of the lower affinity variants PEPT2*1/*2 and PEPT2*2/*2 (mean±SD eGFR: 54.4±19.1, 66.6±23.8, and 78.1±19.9 ml/min per 1.73 m2, respectively). Change in eGFR (mean±SD) over the 10-year period was -11.0±3.3, -2.4±1.9, and 3.4±2.6 ml/min per 1.73 m2 for PEPT2*1/*1, PEPT2*1*2, and PEPT*2*2*2 carriers, respectively. At the end of follow-up, 68% of PEPT2*1*1 carriers had an eGFR<60 ml/min per 1.73 m2, compared with 37% of PEPT2*1*2 carriers and 15% of PEPT2*2*2 carriers. Multiple regression models including all confounders indicated that the PEPT2*1*1 genotype independently associated with an eGFR<60 ml/min per 1.73 m2 (odds ratio, 6.85; 95% confidence interval, 1.34 to 46.20) and an annual decrease in eGFR of >1 ml/min per 1.73 m2 (odds ratio, 3.64; 95% confidence interval, 1.37 to 9.91). Thus, a gene variant is predictive of the severity of a chronic complication of AIP. The therapeutic value of PEPT2 inhibitors in preventing porphyria-associated kidney disease warrants investigation.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Tchernitchko D, Tavernier Q, Lamoril J, et al. A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease. J Am Soc Nephrol. 2016. PMID: 28031405. doi:10.1681/ASN.2016080918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。